Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Ophthalmology

Prevalence

2000.0 / 100K

Incidence

200.0 / 100K/yr

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)?

There are 1 clinical trial targeting Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) tracked by BioSniper.

What is the prevalence of Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)?

The estimated prevalence of Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) is approximately 2000.0 per 100,000 population.

Deep-dive into Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) — Drugs in Development & Clinical Trials | BioSniper